Bod Australia Limited advises that Mr. Patrice Malard has retired as a Non-Executive Director. Mr. Malard joined the Board of Directors following the company's exclusive agreement with NewH2, the innovation arm of exclusive global partner Health & Happiness Group Limited to commercialise Bod's CBD products for relevant global markets. Bod has benefited from Mr. Malard's extensive experience and advice and wish him well for his future endeavours. Mr. Malard will be replaced by Mr. Hanno Cappon, who will act as a representative of NewH2 and H&H. Mr. Cappon will be appointed as a Non-Executive Director, effective immediately. Mr. Cappon is currently Chief Technology Officer at H&H, a position which he has held since January 2021. He has an extensive background in chemistry, life sciences, nutrition and health innovation and developing new consumer and healthcare solutions for commercialisation. Mr. Cappon's previous senior roles with large international companies include VP R&D Nutritionals & Digestive Health at Bayer Consumer Health, Switzerland, as well as VP R&D Nutricia Medical Nutrition at leading multinational food company Danone Nutricia, Netherlands, amongst others. The appointment of Mr. Cappon highlights Bod's ongoing relationship with H&H and brings additional technical and product development experience to the Company's management team. Bod looks forward to leveraging his established relationships and expertise to progress the introduction of new products and continuing commercialisation initiatives.